Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Shares Acquired by Barclays PLC

Barclays PLC boosted its position in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 187.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 219,331 shares of the biotechnology company’s stock after purchasing an additional 143,072 shares during the period. Barclays PLC’s holdings in Aurinia Pharmaceuticals were worth $1,607,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently added to or reduced their stakes in the company. CWM LLC raised its stake in shares of Aurinia Pharmaceuticals by 247.7% during the 3rd quarter. CWM LLC now owns 11,483 shares of the biotechnology company’s stock worth $84,000 after buying an additional 8,180 shares in the last quarter. B. Riley Wealth Advisors Inc. acquired a new position in Aurinia Pharmaceuticals during the second quarter worth $84,000. FMR LLC raised its position in Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 3,919 shares in the last quarter. PFG Investments LLC lifted its holdings in Aurinia Pharmaceuticals by 37.9% in the second quarter. PFG Investments LLC now owns 28,750 shares of the biotechnology company’s stock valued at $164,000 after acquiring an additional 7,900 shares during the period. Finally, China Universal Asset Management Co. Ltd. boosted its position in shares of Aurinia Pharmaceuticals by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 27,502 shares of the biotechnology company’s stock worth $202,000 after purchasing an additional 10,700 shares in the last quarter. Hedge funds and other institutional investors own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Trading Down 3.2 %

NASDAQ:AUPH opened at $8.07 on Friday. Aurinia Pharmaceuticals Inc. has a 52-week low of $4.71 and a 52-week high of $10.67. The company has a quick ratio of 5.11, a current ratio of 5.60 and a debt-to-equity ratio of 0.17. The stock has a fifty day simple moving average of $8.74 and a 200-day simple moving average of $7.23. The company has a market capitalization of $1.16 billion, a PE ratio of -53.80 and a beta of 1.24.

Insider Buying and Selling at Aurinia Pharmaceuticals

In other Aurinia Pharmaceuticals news, Director Jeffrey Allen Bailey sold 4,557 shares of the stock in a transaction on Monday, November 11th. The stock was sold at an average price of $8.43, for a total transaction of $38,415.51. Following the sale, the director now owns 13,356 shares in the company, valued at approximately $112,591.08. This represents a 25.44 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.30% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

AUPH has been the subject of a number of research analyst reports. StockNews.com upgraded shares of Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a report on Monday, September 16th. One research analyst has rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $10.00.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.